Gastroenteropancreatic neuroendocrine neoplasm
Gastroenteropancreatic neuroendocrine neoplasm
Also known as:GEP-NEN, GEP-NET, GI or pancreatic neuroendocrine neoplasm, China Second Rare Disease Catalog item 31
Gastroenteropancreatic neuroendocrine neoplasms are rare tumors from neuroendocrine cells in the digestive tract or pancreas; some grow slowly, while others secrete hormones that cause diarrhea, flushing, hypoglycemia, or ulcer symptoms.
Start Here
A quick guide to the next step: which department to start with, what to prepare, and what to ask.
If endoscopy, imaging, or pathology suggests a neuroendocrine tumor, seek multidisciplinary review at a center with oncology, GI or pancreatic surgery, pathology, radiology, and nuclear medicine experience.
GEP-NEN includes neuroendocrine tumors from the stomach, intestine, appendix, rectum, and pancreas. Treatment planning depends on site, differentiation, Ki-67 or mitotic index, spread, and whether hormones are causing symptoms.
Options may include surgery, endoscopic or ablative therapy, somatostatin analogs, targeted therapy, peptide receptor radionuclide therapy, chemotherapy, and liver-directed therapy.
Most cases are sporadic. Younger onset, multifocal pancreatic NETs, parathyroid or pituitary tumors, or strong family history should prompt evaluation for MEN1, VHL, NF1, or related syndromes.
Nonfunctional tumors may be silent. Functional tumors may be mislabeled as irritable bowel syndrome, ulcer disease, hypoglycemia, menopause-like flushing, or allergy.
This page helps patients and families organize care leads. It does not replace a clinician’s diagnosis or treatment plan. For testing, medication, referrals, emergency care, and support applications, follow qualified clinicians, medical institutions, support organizations, and official sources.
Diagnosis Path
Organized around the practical patient journey: identify clues, avoid common delays, then prepare for care.
When to Suspect It
- Recurrent flushing, diarrhea, wheezing, hypoglycemia, difficult ulcers, abdominal pain, or weight loss has no clear explanation.
- Endoscopy or imaging finds a GI, pancreatic, or liver lesion and pathology shows synaptophysin or chromogranin A positivity.
- The tumor appears slow-growing but recurs, spreads, or causes hormone-related symptoms.
- There are multiple endocrine tumors, hyperparathyroidism, pituitary tumor, or a family history suggesting an inherited syndrome.
Common Wrong Turns
- Treating repeated GI or hormone-like symptoms without considering a neuroendocrine tumor.
- Accepting a NET label without confirming differentiation, grade, Ki-67, and primary site.
- Arriving at a new center without pathology slides, immunostains, DICOM imaging, or surgery records.
- Treating liver metastases as a primary liver cancer without reviewing the original tumor markers.
Departments to Start With
- Medical oncology
- GI or pancreatic surgery
- Gastroenterology
- Pathology or molecular diagnostics
Before the Visit
- Bring endoscopy, contrast CT/MRI, PET or somatostatin receptor imaging, pathology, and immunohistochemistry reports.
- Track flushing, diarrhea, hypoglycemia, ulcers, wheezing, weight change, and medication response.
- Record Ki-67, differentiation, mitotic count, liver spread, and all prior treatments or surgery.
- If a genetic syndrome is possible, collect family history of parathyroid, pituitary, pancreatic, or related tumors.
Tests to Ask About
- Pathology review for differentiation, NET versus NEC, Ki-67, mitotic count, and neuroendocrine markers.
- Staging and receptor assessment with contrast CT/MRI, endoscopic ultrasound, somatostatin receptor PET/CT, or other nuclear imaging.
- Symptom-directed hormone tests such as 5-HIAA, gastrin, insulin/C-peptide, glucagon, or others.
- MEN1, VHL, NF1, or related genetic syndrome evaluation when the pattern fits.
Questions for the Doctor
- Is this a NET or NEC, and what are the grade, Ki-67, and primary site?
- Is the goal cure, long-term control, hormone symptom relief, or reducing tumor burden?
- Am I a candidate for surgery, somatostatin analogs, PRRT, targeted therapy, or chemotherapy?
- Which imaging and markers will be used for follow-up, and how often?
Basic Information
Medical Notes
More complete medical explanations are kept here for discussion with clinicians.
Symptoms
GEP-NEN may cause no symptoms, or may cause abdominal pain, GI bleeding, obstruction, jaundice, or weight loss based on location. Functional tumors can produce flushing, diarrhea, hypoglycemia, recurrent ulcers, rash, wheezing, or electrolyte problems.
Some patients are first diagnosed after liver metastases, incidental imaging, or a small endoscopic lesion. Symptoms depend on site, size, differentiation, spread, and hormone secretion.
Diagnosis
Diagnosis relies on pathology and immunohistochemistry, with documentation of NET versus NEC, differentiation, Ki-67 index, and mitotic count. Imaging and endoscopy help find the primary site and stage disease.
Clinicians distinguish GEP-NEN from adenocarcinoma, pancreatic cancer, liver cancer, lymphoma, inflammatory disease, and other causes of similar hormone symptoms.
Treatment
Localized disease may be treated with surgery or endoscopic/local therapy. Progressive or metastatic disease may be treated with somatostatin analogs, targeted therapy, PRRT, chemotherapy, liver-directed therapy, or clinical trials.
Functional tumors also need symptom control for diarrhea, hypoglycemia, or excess acid. Care is usually multidisciplinary.
Long-term Care
Follow-up monitors tumor growth, hormone symptoms, nutrition, gallbladder, glucose, liver function, treatment side effects, and emotional support. Keep pathology, imaging DICOM files, molecular results, and a treatment timeline.
Fertility and Family
Most GEP-NENs are not inherited. If MEN1, VHL, NF1, or another syndrome is suspected, genetic counseling can guide relative screening and reproductive planning.
When to Seek Urgent Care
Seek urgent care for heavy GI bleeding, black stool with dizziness, bowel obstruction symptoms, severe hypoglycemia, dehydration from diarrhea, rapidly worsening jaundice, infection with fever, or severe treatment reactions.
Prognosis
Outlook varies widely by primary site, differentiation, grade, Ki-67, spread, functional symptoms, and treatment access.